Lotus Pharmaceuticals
1795:TWTaipei, Taiwan· Est.
Taiwan‑based specialty pharma delivering oncology‑focused generics, biosimilars and NCEs across 90+ markets.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
Taiwan‑based specialty pharma delivering oncology‑focused generics, biosimilars and NCEs across 90+ markets.
OncologyImmunology
Technology Platform
Integrated specialty pharma platform combining advanced synthetic chemistry, 505(b)(2) regulatory pathways, and biologics manufacturing for generics, biosimilars and novel compounds.
Opportunities
Expansion of biosimilar and complex generic portfolios in fast‑growing Asian markets, and leveraging strategic acquisitions to broaden geographic reach.
Risk Factors
Regulatory delays, intense competition from multinational generics and biosimilar firms, and integration risk from recent acquisitions.
Competitive Landscape
Competes with global specialty players such as Sandoz, Pfizer, and Novartis; differentiation stems from its integrated 505(b)(2) expertise and strong regional manufacturing network.